Thyroid Carcinoma, Version 2.2022 NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

Robert I. Haddad; Lindsay Bischoff; Douglas Ball; Victor Bernet; Erik Blomain; Naifa Lamki Busaidy; Michael Campbell; Paxton Dickson; Quan Yang Duh; Hormoz Ehya; Whitney S. Goldner; Theresa Guo; Megan Haymart; Shelby Holt; Jason P. Hunt; Andrei Iagaru; Fouad Kandeel; Dominick M. Lamonica; Susan Mandel; Stephanie Markovina; Bryan McIver; Christopher D. Raeburn; Rod Rezaee; John A. Ridge; Mara Y. Roth; Randall P. Scheri; Jatin P. Shah; Jennifer A. Sipos; Rebecca Sippel; Cord Sturgeon; Thomas N. Wang; Lori J. Wirth; Richard J. Wong; Michael Yeh; Carly J. Cassara; Susan Darlow

doi:10.6004/jnccn.2022.0040

Thyroid Carcinoma, Version 2.2022 NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

Robert I. Haddad, Lindsay Bischoff, Douglas Ball, Victor Bernet, Erik Blomain, Naifa Lamki Busaidy, Michael Campbell, Paxton Dickson, Quan Yang Duh, Hormoz Ehya, Whitney S. Goldner, Theresa Guo, Megan Haymart, Shelby Holt, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Dominick M. Lamonica, Susan Mandel, Stephanie MarkovinaBryan McIver, Christopher D. Raeburn, Rod Rezaee, John A. Ridge, Mara Y. Roth, Randall P. Scheri, Jatin P. Shah, Jennifer A. Sipos, Rebecca Sippel, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Michael Yeh, Carly J. Cassara, Susan Darlow

Pathology

Research output: Contribution to journal › Article › peer-review

172 Scopus citations

Abstract

Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).

Original language	English
Pages (from-to)	925-951
Number of pages	27
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	20
Issue number	8
DOIs	https://doi.org/10.6004/jnccn.2022.0040
State	Published - Aug 2022

Keywords

Adenocarcinoma/drug therapy
Carcinoma, Neuroendocrine
Humans
Iodine Radioisotopes/therapeutic use
Iodine/therapeutic use
Thyroid Carcinoma, Anaplastic
Thyroid Neoplasms/diagnosis

Access to Document

10.6004/jnccn.2022.0040

Cite this

Haddad, R. I., Bischoff, L., Ball, D., Bernet, V., Blomain, E., Busaidy, N. L., Campbell, M., Dickson, P., Duh, Q. Y., Ehya, H., Goldner, W. S., Guo, T., Haymart, M., Holt, S., Hunt, J. P., Iagaru, A., Kandeel, F., Lamonica, D. M., Mandel, S., ... Darlow, S. (2022). Thyroid Carcinoma, Version 2.2022 NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY. Journal of the National Comprehensive Cancer Network : JNCCN, 20(8), 925-951. https://doi.org/10.6004/jnccn.2022.0040

@article{7c918185c30240e5a2e01c2be712a702,

title = "Thyroid Carcinoma, Version 2.2022 NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY",

abstract = "Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, H{\"u}rthle cell carcinoma).",

keywords = "Adenocarcinoma/drug therapy, Carcinoma, Neuroendocrine, Humans, Iodine Radioisotopes/therapeutic use, Iodine/therapeutic use, Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms/diagnosis",

author = "Haddad, {Robert I.} and Lindsay Bischoff and Douglas Ball and Victor Bernet and Erik Blomain and Busaidy, {Naifa Lamki} and Michael Campbell and Paxton Dickson and Duh, {Quan Yang} and Hormoz Ehya and Goldner, {Whitney S.} and Theresa Guo and Megan Haymart and Shelby Holt and Hunt, {Jason P.} and Andrei Iagaru and Fouad Kandeel and Lamonica, {Dominick M.} and Susan Mandel and Stephanie Markovina and Bryan McIver and Raeburn, {Christopher D.} and Rod Rezaee and Ridge, {John A.} and Roth, {Mara Y.} and Scheri, {Randall P.} and Shah, {Jatin P.} and Sipos, {Jennifer A.} and Rebecca Sippel and Cord Sturgeon and Wang, {Thomas N.} and Wirth, {Lori J.} and Wong, {Richard J.} and Michael Yeh and Cassara, {Carly J.} and Susan Darlow",

year = "2022",

month = aug,

doi = "10.6004/jnccn.2022.0040",

language = "English",

volume = "20",

pages = "925--951",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "8",

}

Haddad, RI, Bischoff, L, Ball, D, Bernet, V, Blomain, E, Busaidy, NL, Campbell, M, Dickson, P, Duh, QY, Ehya, H, Goldner, WS, Guo, T, Haymart, M, Holt, S, Hunt, JP, Iagaru, A, Kandeel, F, Lamonica, DM, Mandel, S, Markovina, S, McIver, B, Raeburn, CD, Rezaee, R, Ridge, JA, Roth, MY, Scheri, RP, Shah, JP, Sipos, JA, Sippel, R, Sturgeon, C, Wang, TN, Wirth, LJ, Wong, RJ, Yeh, M, Cassara, CJ & Darlow, S 2022, 'Thyroid Carcinoma, Version 2.2022 NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 20, no. 8, pp. 925-951. https://doi.org/10.6004/jnccn.2022.0040

TY - JOUR

T1 - Thyroid Carcinoma, Version 2.2022 NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

AU - Haddad, Robert I.

AU - Bischoff, Lindsay

AU - Ball, Douglas

AU - Bernet, Victor

AU - Blomain, Erik

AU - Busaidy, Naifa Lamki

AU - Campbell, Michael

AU - Dickson, Paxton

AU - Duh, Quan Yang

AU - Ehya, Hormoz

AU - Goldner, Whitney S.

AU - Guo, Theresa

AU - Haymart, Megan

AU - Holt, Shelby

AU - Hunt, Jason P.

AU - Iagaru, Andrei

AU - Kandeel, Fouad

AU - Lamonica, Dominick M.

AU - Mandel, Susan

AU - Markovina, Stephanie

AU - McIver, Bryan

AU - Raeburn, Christopher D.

AU - Rezaee, Rod

AU - Ridge, John A.

AU - Roth, Mara Y.

AU - Scheri, Randall P.

AU - Shah, Jatin P.

AU - Sipos, Jennifer A.

AU - Sippel, Rebecca

AU - Sturgeon, Cord

AU - Wang, Thomas N.

AU - Wirth, Lori J.

AU - Wong, Richard J.

AU - Yeh, Michael

AU - Cassara, Carly J.

AU - Darlow, Susan

PY - 2022/8

Y1 - 2022/8

N2 - Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).

AB - Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).

KW - Adenocarcinoma/drug therapy

KW - Carcinoma, Neuroendocrine

KW - Humans

KW - Iodine Radioisotopes/therapeutic use

KW - Iodine/therapeutic use

KW - Thyroid Carcinoma, Anaplastic

KW - Thyroid Neoplasms/diagnosis

UR - http://www.scopus.com/inward/record.url?scp=85136339238&partnerID=8YFLogxK

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000898497800010&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.6004/jnccn.2022.0040

DO - 10.6004/jnccn.2022.0040

M3 - Article

C2 - 35948029

SN - 1540-1405

VL - 20

SP - 925

EP - 951

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 8

ER -

Thyroid Carcinoma, Version 2.2022 NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this